Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Frequently asked questions
What sector does Regencell Bioscience Holdings Ltd (RGC) operate in?
Regencell Bioscience Holdings Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Regencell Bioscience Holdings Ltd (RGC) current stock price?
As of the latest data, Regencell Bioscience Holdings Ltd stock price is $6.76, with a previous close of $7.67. Regencell Bioscience Holdings Ltd lost -$0.91 in the last trading session, representing a -11.86% loss.
What is Regencell Bioscience Holdings Ltd (RGC) current market capitalization?
Regencell Bioscience Holdings Ltd market cap is approximately 3.35 billion.
What is Regencell Bioscience Holdings Ltd (RGC) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Regencell Bioscience Holdings Ltd (RGC) EBITDA?
Regencell Bioscience Holdings Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.02 million.
Does Regencell Bioscience Holdings Ltd (RGC) pay dividends?
No. Regencell Bioscience Holdings Ltd does not pay a dividend.
When is Regencell Bioscience Holdings Ltd (RGC) next earnings report?
Regencell Bioscience Holdings Ltd is expected to release its next earnings report on September 30, 2026.
What is Regencell Bioscience Holdings Ltd (RGC) beta (volatility) score?
Regencell Bioscience Holdings Ltd has a beta of 1.166, meaning its volatility is roughly in line with the market.
